Ruiz Gutierrez M, Bölükbaşı Ö, Alexe G, Kotini A, Ballotti K, Joyce C, et al. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells. JCI Insight. 2019;5: pubmed publisher

Tian P, Elefanty A, Stanley E, Durnall J, Thompson L, Elwood N. Creation of GMP-Compliant iPSCs From Banked Umbilical Cord Blood. Front Cell Dev Biol. 2022;10:835321 pubmed publisher

Leavens K, Liao C, Gagne A, Kishore S, Cardenas Diaz F, French D, et al. Generation of a double insulin and somatostatin reporter line, SCSe001-A-3, for the advancement of stem cell-derived pancreatic islets. Stem Cell Res. 2020;50:102112 pubmed publisher

Bozaoglu K, Shern Lee W, Haebich K, North K, Payne J, Lockhart P. Generation of four iPSC lines from Neurofibromatosis Type 1 patients. Stem Cell Res. 2020;49:102013 pubmed publisher

Völkner C, Peter F, Liedtke M, Krohn S, Lindner I, Murua Escobar H, et al. Generation of the Niemann-Pick type C2 patient-derived iPSC line AKOSi001-A. Stem Cell Res. 2019;41:101606 pubmed publisher

Bozaoglu K, Gao Y, Stanley E, Fanjul Fernandez M, Brown N, Pope K, et al. Generation of seven iPSC lines from peripheral blood mononuclear cells suitable to investigate Autism Spectrum Disorder. Stem Cell Res. 2019;39:101516 pubmed publisher

Howden S, Hosseini Far H, Motazedian A, Elefanty A, Stanley E, Lamande S, et al. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line. Stem Cell Res. 2019;38:101453 pubmed publisher

Hosseini Far H, Patria Y, Motazedian A, Elefanty A, Stanley E, Lamande S, et al. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing. Stem Cell Res. 2019;37:101449 pubmed publisher

Maguire J, Gagne A, Gonzalez Alegre P, Davidson B, Shakkottai V, Gadue P, et al. Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene. Stem Cell Res. 2019;34:101361 pubmed publisher

Vlahos K, Sourris K, Mayberry R, McDonald P, Bruveris F, Schiesser J, et al. Generation of iPSC lines from peripheral blood mononuclear cells from 5 healthy adults. Stem Cell Res. 2019;34:101380 pubmed publisher

Gagne A, Maguire J, Gandre Babbe S, Chou S, Tasian S, Loh M, et al. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. Stem Cell Res. 2018;31:157-160 pubmed publisher

Slamecka J, McClellan S, Wilk A, Laurini J, Manci E, Hoerstrup S, et al. Induced pluripotent stem cells derived from human amnion in chemically defined conditions. Cell Cycle. 2018;17:330-347 pubmed publisher

Huggins I, Bos T, Gaylord O, Jessen C, Lonquich B, Puranen A, et al. The WNT target SP5 negatively regulates WNT transcriptional programs in human pluripotent stem cells. Nat Commun. 2017;8:1034 pubmed publisher

Chen X, Janssen J, Liu J, Maggio I, t Jong A, Mikkers H, et al. In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting. Nat Commun. 2017;8:657 pubmed publisher

Chao M, Gentles A, Chatterjee S, Lan F, Reinisch A, Corces M, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. 2017;20:329-344.e7 pubmed publisher

Slamecka J, Salimova L, McClellan S, van Kelle M, Kehl D, Laurini J, et al. Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions. Cell Cycle. 2016;15:234-49 pubmed publisher